Strategic Initiative

Slingshot members are tracking this corporate initiative:

Insmed (INSM) and AstraZeneca (AZN) Announce Worldwide License Agreement Giving INSM Global Exclusive Rights to Develop AZD7986 in Non-Cystic Fibrosis Bronchiectasis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Oct 05, 2016
Projected Implementation:
Q1, 2017
Relevance Tracked Until:
Q1, 2019
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Worldwide License Agreement, Global Exclusive Rights, Azd7986, Non-cystic Fibrosis Bronchiectasis